Advanced
Cell Technology, Inc. (“ACT”; OTCBB: ACTC) is a biotechnology company
developing cellular therapies for the treatment of diseases that impact millions
of people worldwide. The company is currently conducting the only ongoing human
embryonic stem cell (hESC)-based human clinical trials in the US and the
first such trial in the EU. (advancedcell.com)
They have released some news on the 14th of this month stated that they are going to attend a meeting tomorrow, June 19, 2012 concerning some studies on embryo.
Advanced
Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of
regenerative medicine, announced today that the company is presenting at two
upcoming conferences: the 2012 Bio International Convention and Clinical Outlooks
for Regenerative Medicine meeting, both in Boston, on Tuesday, June 19. The
presentations will cover the company's three ongoing clinical trials using
human embryonic stem cell-derived retinal pigment epithelial cells to treat
macular degeneration, and other programs. (advancedcell.com)
Stocks in the medical field always tend to do good most of the time after a meeting or a new venture. Could it be the same for ACTC?
Only time will tell, but at the mean time stay tune for the updates on this matter.
Good luck trading!
No comments:
Post a Comment